Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

SLDB

Insider Sentiment (TTM):

Last Purchase:2025-03-11Last Sale:2026-02-18Shares Purchased (TTM):0Shares Sold (TTM):427,620

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:95,756,890Shares Outstanding:109,811,461Institutional Ownership Pct.:87.20%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	159	297	60	61	139	211	80	64	96	118	74	49
Available For Sale Securities Debt Securities Curr…	218	84	128	175	129	96	69	107	94	88	50	94
Prepaid Expense And Other Assets Current	17	15	16	9	11	6	8	8	7	8	6	5
Restricted Cash Current	1	1	1	-	0	0	0	-	-	-	-	-
Assets Current	395	397	205	245	279	313	157	179	198	214	130	148
Assets Noncurrent
Operating Lease Right Of Use Asset	21	21	22	23	23	24	24	25	26	26	27	27
Property Plant And Equipment Net	4	4	4	4	4	4	5	5	5	6	7	7
Other Assets Noncurrent	0	0	0	0	0	0	0	0	1	0	0	0
Restricted Cash Noncurrent	1	1	1	2	2	2	2	2	2	2	2	2
Assets Noncurrent	25	26	27	29	30	30	31	32	33	-	35	-
Assets	421	423	233	274	308	344	189	212	231	249	165	185
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	6	3	8	5	6	4	3	3	2	2	2
Accrued Liabilities Current	18	19	19	19	17	15	20	13	10	10	10	11
Operating Lease Liability Current	2	2	2	2	2	2	2	2	2	2	2	2
Finance Lease Liability Current	-	-	0	0	1	1	1	1	1	0	0	-
Other Liabilities Current	-	-	-	-	-	-	-	-	-	0	0	0
Derivative Liabilities Current	4	3	9	7	6	5	3	3	-	-	0	-
Liabilities Current	29	30	33	36	30	29	30	23	15	14	15	16
Liabilities Noncurrent
Operating Lease Liability Noncurrent	18	18	19	20	20	21	21	22	22	23	23	23
Finance Lease Liability Noncurrent	-	-	-	-	-	-	0	0	1	1	1	-
Liabilities Noncurrent	18	18	19	20	20	21	21	22	23	-	24	-
Liabilities	47	49	53	56	50	49	51	45	38	38	38	40
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,443	1,389	1,138	1,126	1,120	1,117	921	908	901	894	785	783
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	0	0	0	-0	-0	0	0
Retained Earnings Accumulated Deficit	-1,069	-1,015	-958	-908	-862	-823	-783	-741	-708	-683	-659	-638
Stockholders Equity	374	374	180	218	258	294	137	167	193	211	126	144
Liabilities And Stockholders Equity	421	423	233	274	308	344	189	212	231	249	165	185
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	240	240	240	240	240	120	120	120	120	60	60	60
Common Stock Shares Issued	105	98	79	78	78	77	40	39	39	38	20	20
Shares Outstanding	105	98	79	78	78	77	40	39	39	38	20	20

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-13.21%	40.41%	4.40%	-	-	-	-	-	-	-	-	-
2025	75.29%	94.21%	163.71%	-8.94%	-2.32%	-10.76%	4.42%	12.31%	26.92%	12.64%	2.11%	-5.90%
2024	-16.82%	-39.42%	-18.99%	11.25%	-9.74%	-21.12%	-7.17%	-30.94%	-47.72%	-21.45%	-40.00%	-48.91%
2023	-	-	-	-16.62%	-37.14%	-26.23%	7.89%	120.07%	186.02%	-0.57%	-17.42%	-32.46%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	13.82	13.10	6.14	6.74	9.34	10.89	5.20	7.85	13.45	14.94	8.94	9.38
Quick Ratio	13.24	12.59	5.65	6.50	8.98	10.66	4.92	7.49	12.95	14.37	8.52	9.03
Working Capital	366.52M	366.51M	171.98M	208.51M	248.79M	284.63M	127.05M	156.64M	182.92M	199.85M	115.22M	132.53M
Leverage & Debt
Debt to Equity	0.12	0.13	0.29	0.26	0.19	0.17	0.37	0.27	0.20	0.18	0.30	0.28
Interest Coverage TTM	-622.15	-489.93	-382.10	-314.84	-550.26	-456.61	-381.55	-187.14	-160.56	-153.38	-155.14	-344.83
Debt Ratio	0.11	0.12	0.23	0.20	0.16	0.14	0.27	0.21	0.16	0.15	0.23	0.22
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Per Share Metrics
Diluted EPS TTM	-1.44	-1.75	-1.99	-1.77	-1.64	-2.11	-3.06	-2.47	-2.22	-2.37	-4.83	-4.53
Free Cash Flow Per Share TTM	-1.20	-1.57	-1.80	-1.07	-0.97	-1.62	-2.47	-2.21	-2.11	-2.43	-4.81	-5.49
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-6,054.70%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-4,718.44%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-68.80%
Net Income Growth (1Y)	34.41%	37.30%	39.80%	63.16%	69.90%	54.77%	29.87%	12.78%	0.48%	-0.52%	11.67%	1.55%
EPS Growth (1Y)	-11.94%	-17.05%	-34.79%	-28.38%	-26.12%	-10.99%	-36.73%	-45.41%	-51.73%	-48.98%	-52.20%	-61.86%
Valuation Metrics
P/E TTM	-6.93	-4.12	-2.83	-3.49	-2.98	-1.76	-1.31	-2.82	-2.56	-5.63	-1.27	-0.56
P/B TTM	3.84	2.11	2.74	2.67	1.77	0.83	1.19	1.73	1.20	2.41	0.97	0.35
P/S TTM	-	-	-	-	-	-	-	-	-	-	-	26.26
Market Cap	1.44B	790.64M	493.53M	582.56M	458.46M	245.46M	163.27M	288.86M	232.10M	508.23M	122.09M	50.55M
Enterprise Value	1.28B	493.54M	431.64M	519.55M	318.56M	35.93M	84.26M	223.89M	135.81M	390.42M	47.94M	-319.71K
Calculated Values
Free Cash Flow TTM	-172.42M	-172.86M	-157.44M	-101.20M	-91.36M	-107.30M	-100.67M	-91.73M	-86.29M	-92.54M	-95.70M	-110.12M
Net Debt	-159.39M	-297.10M	-61.89M	-63.01M	-139.90M	-209.53M	-79.00M	-64.97M	-96.29M	-117.81M	-74.15M	-50.87M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-18Sale

Owner: Howton, David T

Title: Chief Operating Officer

Shares: 7,469

Price/Share: $5.82

Value: $43,469.58

Shares Owned: 105,077

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Tan, Kevin

Title: CFO & Treasurer

Shares: 5,404

Price/Share: $5.82

Value: $31,451.28

Shares Owned: 99,422

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Hanrahan, Jessie

Title: Chief Regulatory Officer

Shares: 4,134

Price/Share: $5.82

Value: $24,059.88

Shares Owned: 74,318

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Brooks, Gabriel

Title: Chief Medical Officer

Shares: -

Price/Share: $5.82

Value: -

Shares Owned: 89,466

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Herzich, Paul

Title: Chief Technology Officer

Shares: 3,616

Price/Share: $5.82

Value: $21,045.12

Shares Owned: 72,638

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-18	Howton, David T	Officer	Chief Operating Officer	Direct	Sale	7,469	5.82	$43,469.58	105,077	4
2026-02-18	Tan, Kevin	Officer	CFO & Treasurer	Direct	Sale	5,404	5.82	$31,451.28	99,422	4
2026-02-18	Hanrahan, Jessie	Officer	Chief Regulatory Officer	Direct	Sale	4,134	5.82	$24,059.88	74,318	4
2026-02-18	Brooks, Gabriel	Officer	Chief Medical Officer	Direct	Sale	0	5.82	$0.00	89,466	4
2026-02-18	Herzich, Paul	Officer	Chief Technology Officer	Direct	Sale	3,616	5.82	$21,045.12	72,638	4
2026-02-18	Cumbo, Alexander	Director,Officer	President and CEO	Direct	Sale	16,644	5.82	$96,868.08	235,405	4
2026-02-18	Ganot, Ilan	Director	-	Indirect	Sale	2,658	5.82	$15,469.56	27,474	4
2026-02-04	Cumbo, Alexander	Director,Officer	President and CEO	Direct	Sale	48,913	6.44	$314,999.72	222,018	4
2026-02-04	Herzich, Paul	Officer	Chief Technology Officer	Direct	Sale	10,905	6.44	$70,228.20	69,067	4
2026-02-04	Ganot, Ilan	Director	-	Indirect	Sale	7,205	6.44	$46,400.20	25,271	4
2026-02-04	Tan, Kevin	Officer	CFO & Treasurer	Direct	Sale	14,783	6.44	$95,202.52	94,201	4
2026-02-04	Hanrahan, Jessie	Officer	Chief Regulatory Officer	Direct	Sale	12,348	6.44	$79,521.12	70,327	4
2026-02-04	Howton, David T	Officer	Chief Operating Officer	Direct	Sale	18,894	6.44	$121,677.36	97,859	4
2026-02-04	Brooks, Gabriel	Officer	Chief Medical Officer	Direct	Sale	12,616	6.44	$81,247.04	84,092	4
2026-02-02	Hanrahan, Jessie	Officer	Chief Regulatory Officer	Direct	Sale	26,535	6.44	$170,885.40	82,675	4
2026-02-02	Brooks, Gabriel	Officer	Chief Medical Officer	Direct	Sale	28,335	6.44	$182,477.40	96,708	4
2026-02-02	Cumbo, Alexander	Director,Officer	President and CEO	Direct	Sale	80,258	6.44	$516,861.52	270,931	4
2026-02-02	Herzich, Paul	Officer	Chief Technology Officer	Direct	Sale	26,250	6.44	$169,050.00	79,972	4
2026-02-02	Howton, David T	Officer	Chief Operating Officer	Direct	Sale	37,771	6.44	$243,245.24	116,753	4
2026-02-02	Tan, Kevin	Officer	CFO & Treasurer	Direct	Sale	26,837	6.44	$172,830.28	108,984	4
2026-01-28	Ganot, Ilan	Director	-	Indirect	Sale	191	6.59	$1,258.69	17,476	4
2026-01-13	Tan, Kevin	Officer	CFO & Treasurer	Direct	Sale	5,704	5.27	$30,060.08	46,100	4
2026-01-05	Ganot, Ilan	Director	-	Indirect	Sale	1,053	5.43	$5,717.79	17,278	4
2025-12-03	Cumbo, Alexander	Director,Officer	President and CEO	Direct	Sale	10,808	5.11	$55,228.88	81,388	4
2025-12-03	Hanrahan, Jessie	Officer	Chief Regulatory Officer	Direct	Sale	4,483	5.11	$22,908.13	26,660	4
2025-12-03	Herzich, Paul	Officer	Chief Technology Officer	Direct	Sale	2,701	5.11	$13,802.11	26,622	4
2025-12-03	Howton, David T	Officer	Chief Operating Officer	Direct	Sale	4,932	5.11	$25,202.52	32,908	4
2025-11-10	Ganot, Ilan	Director	-	Direct	Sale	3,278	4.12	$13,505.36	95,412	4
2025-10-20	Brooks, Gabriel	Officer	Chief Medical Officer	Direct	Sale	2,895	5.96	$17,254.20	33,819	4
2025-03-11	Kahn, Clare	Director	-	Direct	Purchase	1,860	5.34	$9,932.40	2,960	4
2025-02-19	Edelman, Joseph, Percepti…	Director,TenPercentOwner	-	Indirect	Purchase	5,000,000	4.03	$20,150,000.00	11,833,539	4
2025-02-19	Bcls, Sb Investco, Lp, Ba…	TenPercentOwner	-	Indirect	Purchase	1,000,000	4.03	$4,030,000.00	5,034,582	4
2025-02-18	Atchinson, Robert, Adage …	TenPercentOwner	-	Indirect	Purchase	252,545	7.56	$1,909,240.20	4,248,084	4
2025-02-14	Tan, Kevin	Officer	CFO & Treasurer	Direct	Sale	3,164	3.96	$12,529.44	32,250	4
2025-02-14	Cumbo, Alexander	Director,Officer	President and CEO	Direct	Sale	11,365	3.96	$45,005.40	60,717	4
2025-02-14	Howton, David T	Officer	Chief Operating Officer	Direct	Sale	5,561	3.96	$22,021.56	24,789	4
2025-02-14	Herzich, Paul	Officer	Chief Technology Officer	Direct	Sale	2,688	3.96	$10,644.48	18,388	4
2025-02-14	Hanrahan, Jessie	Officer	Chief Regulatory Officer	Direct	Sale	3,079	3.96	$12,192.84	19,281	4
2025-02-14	Brooks, Gabriel	Officer	Chief Medical Officer	Direct	Sale	3,256	3.96	$12,893.76	22,812	4
2025-02-14	Ganot, Ilan	Director	-	Indirect	Sale	1,711	3.96	$6,775.56	14,839	4
2025-01-28	Ganot, Ilan	Director	-	Indirect	Sale	144	3.11	$447.84	11,689	4
2025-01-10	Tan, Kevin	Officer	CFO & Treasurer	Direct	Sale	4,073	3.89	$15,843.97	24,789	4
2025-01-06	Ganot, Ilan	Director	-	Indirect	Sale	1,056	4.31	$4,551.36	11,445	4
2024-12-03	Hanrahan, Jessie	Officer	Chief Regulatory Officer	Direct	Sale	4,610	5.60	$25,816.00	14,235	4
2024-12-03	Cumbo, Alexander	Director,Officer	President and CEO	Direct	Sale	11,114	5.60	$62,238.40	38,484	4
2024-12-03	Herzich, Paul	Officer	Chief Technology Officer	Direct	Sale	2,777	5.60	$15,551.20	12,182	4
2024-12-03	Howton, David T	Officer	Chief Operating Officer	Direct	Sale	5,072	5.60	$28,403.20	15,663	4
2024-10-21	Brooks, Gabriel	Officer	Chief Medical Officer	Direct	Sale	2,923	6.50	$18,999.50	10,979	4
2024-06-07	Kahn, Clare	Director	-	Direct	Purchase	1,100	7.67	$8,437.00	1,100	4
2024-05-02	Ganot, Ilan	Director	-	Indirect	Sale	462	10.33	$4,772.46	9,507	4
2024-01-29	Ganot, Ilan	Director	-	Indirect	Sale	139	7.99	$1,110.61	8,416	4
2024-01-11	Perceptive, Xontogeny Ven…	Director,TenPercentOwner	-	Indirect	Purchase	3,410,713	5.53	$18,861,242.89	6,833,539	4
2024-01-11	Ra, Capital Nexus Fund, L…	Director,TenPercentOwner	-	Indirect	Purchase	904,160	5.53	$5,000,004.80	4,192,216	4
2024-01-09	Tan, Kevin	Officer	CFO & Treasurer	Direct	Sale	3,935	8.20	$32,267.00	9,308	4
2024-01-03	Ganot, Ilan	Director	-	Indirect	Sale	1,142	5.30	$6,052.60	8,167	4
2023-12-04	Hanrahan, Jessie	Officer	Chief Regulatory Officer	Direct	Sale	4,879	2.78	$13,563.62	6,983	4
2023-12-04	Marlowe, Jennifer	Officer	CSO	Direct	Sale	4,890	2.77	$13,545.30	6,998	4
2023-12-04	Howton, David T	Officer	Chief Operating Officer	Direct	Sale	5,367	2.78	$14,920.26	7,684	4
2023-12-04	Herzich, Paul	Officer	Chief Technology Officer	Direct	Sale	2,968	2.77	$8,221.36	4,270	4
2023-12-04	Cumbo, Alexander	Director,Officer	President and CEO	Direct	Sale	11,757	2.77	$32,566.89	17,439	4
2023-05-02	Ganot, Ilan	Director	-	Indirect	Sale	487	4.85	$2,361.95	4,153	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

87.20%

Inst. Shares: 95,756,890

Shares Outstanding: 109,811,461

2025-12-31

92.87%

Inst. Shares: 81,268,724

Shares Outstanding: 87,504,631

2025-09-30

86.00%

Inst. Shares: 81,200,629

Shares Outstanding: 94,417,746

2025-06-30

86.68%

Inst. Shares: 81,605,177

Shares Outstanding: 94,140,286

2025-03-31

118.65%

Inst. Shares: 78,715,591

Shares Outstanding: 66,341,305

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	95,756,890	109,811,461	87.20%
2025-12-31	81,268,724	87,504,631	92.87%
2025-09-30	81,200,629	94,417,746	86.00%
2025-06-30	81,605,177	94,140,286	86.68%
2025-03-31	78,715,591	66,341,305	118.65%
2024-12-31	36,234,017	40,816,694	88.77%
2024-09-30	35,671,758	41,443,317	86.07%
2024-06-30	37,417,353	40,934,361	91.41%
2024-03-31	34,888,338	38,155,373	91.44%
2023-12-31	14,264,719	19,884,007	71.74%
2023-09-30	13,809,271	20,059,641	68.84%
2023-06-30	13,980,681	19,663,672	71.10%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Solid Biosciences Inc. (SLDB) — SEC Financial Statements & Analysis

Solid Biosciences Inc. (SLDB) is a biological products, (no diagnostic substances) company, incorporated in DE. Solid Biosciences Inc. trades on Nasdaq as: SLDB. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Solid Biosciences Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.12x, a Price-to-Sales (P/S) ratio of 26.26x (TTM), a Price-to-Book (P/B) ratio of 3.84x (TTM), at a market cap of $1.44B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.12x
P/S TTM: 26.26x
P/B TTM: 3.84x
Market Cap: $1.44B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Solid Biosciences Inc. in?

Solid Biosciences Inc. (SLDB) operates in the Biological Products, (No Diagnostic Substances) industry.

What is SLDB's market cap?

Solid Biosciences Inc. (SLDB) has a market capitalization of $1.44B as of 2026-06-30.

What exchange does SLDB trade on?

Solid Biosciences Inc. (SLDB) trades on the Nasdaq.

Where is Solid Biosciences Inc. incorporated?

Solid Biosciences Inc. is incorporated in DE.